ArticleScientific reports2025
Compact Calm1 promoter enables AAV mediated neuron-targeted expression in human iPSC-derived brain organoids.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Compact neuron-specific promoters enable targeted gene expression in the brain, especially when using size-limited adeno-associated virus (AAV) vectors. The human synapsin 1 gene promoter (hSyn) promoter is widely used, but the recently described Calm1 promoter (120 bp long) offers a smaller alternative with demonstrated excitatory and inhibitory neuron-specificity in animal models. Here, we compared the commonly used hSyn promoter and the compact Calm1 promoter in human iPSC-derived brain organoids using AAV reporter constructs. Our study evaluating reporter gene expression and immunohistology showed comparable performance in human neurons. Our findings suggest that the compact Calm1 promoter could be used for future central nervous system-targeted human gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.